Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Retagliptin (SP2086) in Renal Insufficiency
NCT02815774Phase 1Completed
- Sponsor
- Hengrui
- Start
- Jun 2014
- Primary completion
- Jan 2015
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of retagliptin in type 2 diabetes mellitus (T2DM) (5 arms), sponsored by Hengrui. Primary endpoints: Maximum Plasma Concentration of SP2086 up to 96 hours, Maximum Plasma Concentration of SP2086 Acid up to 96 hours and 2 more. Started Jun 2014; status: completed.
02
Drugs
retagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02815774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02815774.